Targeted delivery of panitumumab-scaffold bosutinib-encapsulated polycaprolactone nanoparticles for EGFR-overexpressed colorectal cancer.
Nanomedicine (Lond)
; 18(9): 713-741, 2023 04.
Article
in En
| MEDLINE
| ID: mdl-37309754
ABSTRACT
Aims:
Panitumumab (anti-Erb)-conjugated polycaprolactone (PCL) nanoparticles loaded with bosutinib (BTNB) were used to develop a targeted drug-delivery system for colon cancer cells. Materials &methods:
Using carbodiimide coupling, anti-Erb was conjugated to BTNB-loaded PCL nanoparticles. Dynamic light scattering, scanning electron microscopy, transmission electron microscopy, Fourier-transform infrared spectroscopy, differential scanning calorimetry, x-ray diffraction and thermogravimetric analysis were used to analyze nanoparticles.Results:
According to in vitro studies, anti-Erb-BTNB-PCL nanoparticles inhibited HCT116 cells more than BTNB alone. Cell arrest at different phases was examined for apoptotic potential. An in vivo efficacy study showed that anti-Erb-BTNB-PCL nanoparticles could target tumors selectively.Conclusion:
Anti-Erb-conjugated BTNB nanoparticles could specifically target colon cancer.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Colorectal Neoplasms
/
Colonic Neoplasms
/
Nanoparticles
Limits:
Humans
Language:
En
Year:
2023
Type:
Article